Nutri Advanced News

TMAO – the ‘Cardiovascular Risk Factor’ Encouraging Us to Keep an Open Mind

TMAO – the ‘Cardiovascular Risk Factor’ Encouraging Us to Keep an Open Mind

“If we knew what we were doing, it would not be called research, would it?”
-  Albert Einstein

The most important question a healthcare practitioner or researcher can ask is ‘why?’

Functional medicine is built on a strong foundation of digging deep to uncover the root causes of ill health, and embraces the notion that all bodily systems are interconnected. Every client arrives with a unique health story, so it is crucial to start each consultation with an open mind and a blank sheet of paper.

Adopting the same approach to research is vital; and the current debate surrounding TMAO is a perfect illustration of this.

Much has been written and talked about TMAO recently. TMAO, or tri-methylamine-N-oxide, is a plasma metabolite; higher levels of which have been linked to increased cardiovascular risk. A recent meta-analysis of 11 prospective cohort studies found that higher plasma TMAO correlates with increases in CV risk and all-cause mortality.1 Alongside increasing interest in the compound however a debate is brewing. There are parts of the TMAO puzzle that simply don’t fit. And what is emerging is perhaps another cautionary tale against jumping to premature conclusions.

TMAO is produced from dietary methylamine precursors such as phosphatidylcholine, choline and carnitine. There are then two steps involved in its synthesis. First TMA lyase enzyme activity by gastrointestinal bacteria generate TMA (trimethylamine), and second, circulating TMA is oxidised to TMAO by hepatic FMOs (flavin-containing monooxygenase). TMAO is also supplied directly through the diet in the form of fish (particularly deep-sea fish), which is the primary dietary source of preformed TMAO.

If higher plasma TMAO is linked to increased CV risk then a logical thought progression is that dietary intake of either TMAO precursors (choline, phosphatodylcholine & carnitine) or dietary sources of preformed TMAO (fish) would be associated with CV risk, but this has not been shown to be the case.

A recent meta-analysis of prospective epidemiological studies found that dietary choline has no significant impact on CV disease or mortality risk.2 In another meta-analysis, no association was found between the consumption of eggs (rich in phosphatidylcholine) and CV risk.3 In addition, multiple studies have demonstrated carnitine supplementation to be cardio-protective, even despite its potential to increase TMAO levels.4-14

Perhaps the most puzzling of all is the association between dietary intake of fish (the primary source of preformed TMAO) and reduced cardiovascular risk. Meta-analyses have shown that dietary intake of fish correlates dose dependently with cardiovascular protection.15 Yet fish increases plasma TMAO.

And to add further complexity and confusion; the production of TMAO has been shown to be influenced by differences in the gut microbiome (firmicutes: bacteroidetes ratio / microbial diversity).16 Plasma levels of TMAO are also influenced by renal function, with elevated levels observed in patients with impaired renal function.17

The tangled web of TMAO

With such seeming contradictions, perhaps the only truth here is that there is still much to understand about TMAO before we can be confidently clear on its relevance as a universal biomarker for cardiovascular health.18-20 And if the TMAO tale is a tangled web, here we are looking at a single, fragile thread; this short article by no means promises to unravel the rest. Above all we’re encouraging you to maintain a curious and inquisitive approach to your practice and research.

Amidst the complexity and confusion, the clinical takeaway here is simple.  Keep an open mind.

References:
1. Qi J, You T, et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies. J Cell Mol Med 2018; 22:185–94.
2. Meyer K, Shea J. Dietary choline and betaine and risk of CVD: a systematic review and meta-analysis of prospective studies. Nutrients2017;9 3390/nu9070711
3. Alexander DD, Miller PE, et al. Meta-analysis of egg consumption and risk of coronary heart disease and strokeJ Am Coll Nutr2016; 35: 704–16.
4. Samulak JJ, Sawicka AK et al. L-carnitine supplementation increases trimethylamine-N-oxide but not markers of atherosclerosis in healthy aged women. Ann Nutr Metab 2019; 74 (1): 11-17
5. DiNicolantonio JJ, Lavie CJ, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc2013; 88:544–51.
6. Cherchi A, Lai C, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol1985; 23: 569–72.
7. Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res1991; 17:225–35.
8. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation1988; 77:767–73.
9. Andreozzi GM. Propionyl L-carnitine: Intermittent claudication and peripheral arterial disease. Expert Opin Pharmacother2009; 10:2697–707.
10. Anand I, Chandrashekhan Y, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther1998; 12:291–9.
11. Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung1992; 42: 1101–4.
12. Spagnoli LG, Orlandi A, Marino B, et al. Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits. Atherosclerosis1995; 114:29–44.
13. Sayed-Ahmed MM, Khattab MM, Gad MZ, et al. L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res2001; 44:235–42.
14. Collins HL, Drazul-Schrader D, et al. L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE(-/-) transgenic mice expressing CETP. Atherosclerosis2016; 244: 29–37.
15. He K, Song Y, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation2004;109:2705–11.
16. Cho CE, Taesuwan S et al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: A randomised controlled trial. Mol Nutr Food Res 2017 Jan; 61(1)
17. Missailidis C, Hallqvist J et al. Serum trimethylamine-n-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS One 2016 Jan 11; 11(1): e0141738
18. DiNicolantonio JJ, McCarty M et al. Association of moderately elevated trimethylamine N-oxide with cardiovascular risk: is TMAO serving as a marker for hepatic insulin resistance. Open Heart 2019; 6(1): e000890
19. Cho CE, Caudill MA. Trimethylamine-N-Oxide: Friend, foe, or simply caught in the cross-fire? Trends Endocrinol Metab. 2017 Feb; 28(2):121-130
20. Landfald B, Valeur J et al. Microbial trimethylamine-n-oxide as a disease marker: something fishy? Microb Ecol Health Dis. 2017 May 19; 28(1): 1327309

This website and its content is copyright of Nutri Advanced ©. All rights reserved. See our terms & conditions for more detail.